Advertisment

The Promise and Concerns of CD19-Directed CAR T-Cell Therapy in Autoimmune Diseases

author-image
Anthony Raphael
New Update
NULL

The Promise and Concerns of CD19-Directed CAR T-Cell Therapy in Autoimmune Diseases

Advertisment

Potential of CAR T-Cell Therapy in Autoimmune Diseases

Advertisment

Over the past few years, CD19-directed chimeric antigen receptor (CAR) T-cell therapy has emerged as a revolutionary treatment in the field of immunology. Recently, a study presented at the American Society of Hematology (ASH) annual meeting reported persistent, drug-free remission in 15 patients with systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis. This innovative treatment has shown the potential to lead to complete remission in these patients.

Updates on Immuno-Oncology Pipeline from CRISPR Therapeutics

CRISPR Therapeutics, an industry leader in immuno-oncology, has announced updates on their pipeline of gene-edited allogeneic CAR T cell product candidates. Their next-generation candidates, CTX112 targeting CD19 and CTX131 targeting CD70, are currently undergoing clinical trials. Preliminary data suggest these candidates may improve upon the clinical profile of first-generation treatments due to their enhanced CAR T potency and reduced CAR T exhaustion. CRISPR Therapeutics plans to initiate new clinical trials in additional indications, including autoimmune diseases such as systemic lupus erythematosus, in the first half of 2024.

Advertisment

FDA Safety Warning on CAR T-Cell Therapy

Despite the promising results of CAR T-cell therapies, the FDA has issued a safety warning, raising concerns about the development of T cell malignancies in patients undergoing these treatments. This warning was prompted by reports of secondary cancers subsequent to the administration of certain CAR T cell therapies. However, the benefits of CAR T cell therapies still outweigh the potential risks for now. Continuous monitoring and proactive reporting of adverse events are essential to ensure patient safety.

Application of New Technologies in Healthcare

Advertisment

Emerging technologies are playing a significant role in revolutionizing healthcare. The application of artificial intelligence (AI) is one such example. AI tools are being used to diagnose blood cancers and differentiate between different types of myeloproliferative neoplasms. These tools also analyze patient experiences with diseases like sickle cell disease through social media posts, providing insights into patient perspectives and experiences.

Upcoming CAR T-Cell Therapy Trials

The FDA has approved Cabaletta Bio's investigational new drug (IND) application for a clinical trial in generalized myasthenia gravis (gMG) of CABA 201, a CD19-directed CAR T cell therapy intended to treat autoimmune diseases. Additionally, Kyverna Therapeutics has received IND clearance for an open-label phase 2 clinical trial for its CAR T KYV 101 in patients with MG. Other CAR Ts in development for MG include IASO Biotherapeutics CT103A equecabtagene autoleucel and Cartesian Therapeutics Descartes 08.

Conclusion

Despite the potential risks associated with CD19-directed CAR T-cell therapy, the treatment holds significant promise for patients suffering from autoantibody-dependent autoimmune diseases. As more clinical trials are set to begin in the coming years, the continued development and refinement of these therapies could bring about a new era in autoimmune disease treatment. However, ensuring patient safety remains paramount, and the monitoring and reporting of adverse events will be crucial.

Advertisment
Chat with Dr. Medriva !